Matt Herper over at FORBES suggested I update and repost the “Glimmer of Hope” “Class of 2010″ biotech IPOs blog post, which I’ve now done, and the performance continues to impress:
The average and median performance of this “Class” is 33% and 21%, respectively – which is markedly better than all the recent prior classes’ performance. Ventrus, Aegerion, AVEO, Complete Genomics, and Trius have all appreciated by more than 50% since their IPO.
Pretty impressive returns for the top half the group. I’m still skeptical about most new IPOs, but much of this group certainly seems to be performing well.